{"DataElement":{"publicId":"6242588","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Tumor Lysis Syndrome 5.0 Grade","preferredDefinition":"A description of the common toxicity criteria adverse event version 5.0 tumor lysis syndrome grade.","longName":"2193247v1.0:6242576v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2193247","version":"1","preferredName":"Common Toxicity Criteria Adverse Event Tumor Lysis Syndrome","preferredDefinition":"information related to the CTC adverse event of tumor lysis syndrome.","longName":"CTC_AE_TLS","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2480706","version":"1","preferredName":"Common Terminology Criteria for Adverse Events","preferredDefinition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","longName":"C49704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Common Terminology Criteria for Adverse Events","conceptCode":"C49704","definition":"A standard terminology developed to report adverse events occurring in cancer clinical trials.  Common terminology criteria for adverse events (CTCAE) are used in study adverse event summaries and Investigational New Drug reports to the Food and Drug Administration.  The CTCAE contain a grading scale for each adverse event term representing the severity of the event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"133A63CA-49B0-49FD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-07","modifiedBy":"ONEDATA","dateModified":"2006-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2193245","version":"1","preferredName":"Tumor Lysis Syndrome","preferredDefinition":"A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death. --2004","longName":"Tumor Lysis Syndrome","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Tumor Lysis Syndrome","conceptCode":"C3425","definition":"A condition of metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells. Tumor lysis syndrome typically occurs in aggressive, rapidly proliferating lymphoproliferative disorders. Burkitt lymphoma and T cell acute lymphoblastic leukemia are commonly associated with this syndrome. Metabolic abnormalities include hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia and may result in renal failure, multiple organ failure, and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAC0FC16-1B7D-2297-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-09","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAC0FC16-1B83-2297-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6242576","version":"1","preferredName":"Tumor lysis syndrome 5.0 Grade","preferredDefinition":"A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells._A position on a scale of intensity or amount or quality.","longName":"6242576v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"5","valueDescription":"Grade 5 Tumor Lysis Syndrome, CTCAE","ValueMeaning":{"publicId":"6242578","version":"1","preferredName":"Grade 5 Tumor Lysis Syndrome, CTCAE","longName":"6242578","preferredDefinition":"Death","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 5 Tumor Lysis Syndrome, CTCAE","conceptCode":"C56632","definition":"Death","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B166282-175D-0C92-E053-F662850A690F","latestVersionIndicator":"Yes","beginDate":"2018-05-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-01","modifiedBy":"ONEDATA","dateModified":"2018-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B166282-1776-0C92-E053-F662850A690F","beginDate":"2018-05-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-01","modifiedBy":"ONEDATA","dateModified":"2018-05-01","deletedIndicator":"No"},{"value":"4","valueDescription":"Grade 4 Tumor Lysis Syndrome, CTCAE","ValueMeaning":{"publicId":"6242580","version":"1","preferredName":"Grade 4 Tumor Lysis Syndrome, CTCAE","longName":"6242580","preferredDefinition":"Life-threatening consequences; urgent intervention indicated","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 4 Tumor Lysis Syndrome, CTCAE","conceptCode":"C146159","definition":"Life-threatening consequences; urgent intervention indicated","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B166282-1783-0C92-E053-F662850A690F","latestVersionIndicator":"Yes","beginDate":"2018-05-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-01","modifiedBy":"ONEDATA","dateModified":"2018-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B166282-179C-0C92-E053-F662850A690F","beginDate":"2018-05-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-01","modifiedBy":"ONEDATA","dateModified":"2018-05-01","deletedIndicator":"No"},{"value":"3","valueDescription":"Grade 3 Tumor Lysis Syndrome, CTCAE","ValueMeaning":{"publicId":"6242582","version":"1","preferredName":"Grade 3 Tumor Lysis Syndrome, CTCAE","longName":"6242582","preferredDefinition":"Present","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3 Tumor Lysis Syndrome, CTCAE","conceptCode":"C56620","definition":"Present","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B166282-17A9-0C92-E053-F662850A690F","latestVersionIndicator":"Yes","beginDate":"2018-05-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-01","modifiedBy":"ONEDATA","dateModified":"2018-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B166282-17C2-0C92-E053-F662850A690F","beginDate":"2018-05-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-01","modifiedBy":"ONEDATA","dateModified":"2018-05-01","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008517","version":"1","preferredName":"Adverse Events","preferredDefinition":"any unfavorable symptoms, signs, or disease temporally associated with the use of a medical\r\ntreatment or procedure that may or may not be considered related to the medical\r\ntreatment or procedure.","longName":"AE","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB51E03C-635E-5672-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-09-23","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-09-23","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":"Definition copied from CTC Manual.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6242575","version":"1","preferredName":"Tumor lysis syndrome Grade","preferredDefinition":"A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.:A position on a scale of intensity or amount or quality.","longName":"C146688:C48309","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tumor Lysis Syndrome, CTCAE 5.0","conceptCode":"C146688","definition":"A disorder characterized by metabolic abnormalities that result from a spontaneous or therapy-related cytolysis of tumor cells.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Grade","conceptCode":"C48309","definition":"A position on a scale of intensity or amount or quality.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B166282-1733-0C92-E053-F662850A690F","latestVersionIndicator":"Yes","beginDate":"2018-05-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-01","modifiedBy":"ONEDATA","dateModified":"2018-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B166282-1744-0C92-E053-F662850A690F","latestVersionIndicator":"Yes","beginDate":"2018-05-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-01","modifiedBy":"KUMMEROA","dateModified":"2018-10-23","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"CPST_TOX_ctcae_tum_lysis_grd","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the common toxicity","type":"Preferred Question Text","description":"What was the common toxicity criteria adverse event tumor lysis syndrome 5.0 grade?","url":null,"context":"NHLBI"},{"name":"Grade","type":"Alternate Question Text","description":"Grade","url":null,"context":"NHLBI"},{"name":"Grade","type":"Application Standard Question Text","description":"Grade","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B16C390-3D5E-7CCA-E053-F662850A86E9","latestVersionIndicator":"Yes","beginDate":"2018-05-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-05-01","modifiedBy":"KUMMEROA","dateModified":"2019-12-03","changeDescription":". System generated def displayed as alt def.; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}